VANDA PHARMACEUTICALS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2018-12-31 was $0.00.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $0.00.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2018-06-30 was $2.00K.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2018-03-31 was $100.87M.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2018 was $100.87M.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2014 was $62.31M, a 28.47% increase from fiscal 2013.
- VANDA PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2013 was $48.51M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $100.87M 10-K · filed 2021-02-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | |
| 2018-06-30 | $2.00K 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $100.87M 10-Q · filed 2019-11-07 | |
| 2014-12-31 | $62.31M 10-K · filed 2017-02-17 | |
| 2013-12-31 | -$47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $48.51M 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |